Zydus Lifesciences Limited has informed the Exchange regarding a press release dated May 17, 2024, titled "Zydus and MSN announces exclusive licensing and supply agreement for Cabozantinib Tablets (generic version of CABOMETYX��) for the US market".
Zydus Lifesciences Limited Press Release May 17 2024
Filed with NSE · · 3 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has announced a press release regarding an exclusive licensing and supply agreement for Cabozantinib Tablets for the US market. The agreement involves MSN Laboratories manufacturing and supplying the generic version of CABOMETYX, while Zydus will handle marketing and distribution in the US. This partnership aims to enhance access to affordable medications for cancer patients. The total addressable market for Cabozantinib Tablets in the US is significant, highlighting the potential impact of this collaboration.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
In the deck
Earlier from Zydus Lifesciences
- Press Release May 11 2024
- Press Release May 09 2024
- Press Release May 04 2024
- Press Release Apr 26 2024
- Press Release Apr 23 2024
Later from Zydus Lifesciences
- Press Release May 22 2024
- Press Release May 24 2024
- Press Release Jun 14 2024
- Press Release Jun 28 2024
- Press Release Jul 04 2024
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences